GlassScriptPhysician profile
Desiree Levyim
NPI 1497167985
$5,528.57
in general payments reported to CMS, 2019-2025
33 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 76% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.15 · 2020: $47.55 · 2021: $160 · 2022: $775 · 2023: $1,088 · 2024: $1,716 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468 · Education: $13.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.46 |
| Education | $13.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,012.97 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $605.06 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $568.93 | 2023-2025 | |
| Harmony Biosciences LLC | $533.23 | 2022-2024 | Wakix |
| Novartis Pharmaceuticals Corporation | $371.18 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $348.31 | 2022 | |
| Eisai INC. | $253.14 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $180.32 | 2023-2025 | Nuplazid |
| Neurelis, INC. | $130.53 | 2021-2025 | Valtoco |
| Medtronic, INC. | $127.17 | 2024 | Percept PC Brainsense |
| Jazz Pharmaceuticals INC. | $119.82 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $118.97 | 2024 | Dupixent |
| Sk Life Science, INC. | $117.68 | 2022 | |
| Axsome Therapeutics, INC. | $105.85 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $91.47 | 2023 | Aptiom |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $89.98 | 2025 | Motpoly Xr |
| Biogen, INC. | $88.65 | 2022-2025 | Vumerity |
| Ucb, INC. | $75.58 | 2023-2025 | Rystiggo |
| Mdd US Operations, LLC | $72.70 | 2024 | Apokyn |
| Lundbeck LLC | $65.94 | 2025 | Vyepti, Rexulti |
| Mallinckrodt Enterprises LLC | $64.15 | 2019 | |
| Argenx US, INC. | $55.20 | 2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $51.07 | 2023 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $46.27 | 2021 | |
| Amgen INC. | $43.17 | 2023-2024 | Aimovig, Uplizna |
| Lilly USA, LLC | $36.89 | 2023-2024 | Amyvid |
| Scilex Pharmaceuticals INC. | $27.32 | 2025 | |
| Allergan, INC. | $27.00 | 2022 | |
| Abbott Laboratories | $25.75 | 2025 | Infinity |
| Amneal Pharmaceuticals LLC | $23.99 | 2024 | Rytary |
| Forte Bio-Pharma LLC | $19.12 | 2025 | Tanlor |
| Biomarin Pharmaceutical INC. | $16.58 | 2024 | Brineura |
| Azurity Pharmaceuticals, INC. | $14.58 | 2024 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Levyim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.